'The era of quantum supremacy is just around the corner,' IonQ CEO says
"The era of what's called quantum supremacy is just around the corner," De Masi said. "It's coming in quarters and very low single-digit years, and that's getting people, obviously, pretty excited about the fact that we'll be able to do things to help every area of applied science."
IonQ is one of the major players in the quantum computing space, along with Rigetti Computing, D-Wave Quantum and Quantum Computing. The company is developing both quantum computers and quantum networking equipment, De Masi said.
Wall Street's interest in quantum computing is growing as tech titans like Alphabet, Microsoft, Amazon and IBM, as well as the U.S. government, spend millions to the develop quantum computers. The technology aims to solve problems that are too complex for classical computers using quantum mechanics. Investors were particularly excited by Nvidia CEO Jensen Huang's bullish comments on quantum computing last month. Huang said quantum computing is "reaching an inflection point" and indicated that practical uses cases are coming faster than he previously expected.
De Masi described the way quantum computing could lead to breakthroughs in the healthcare and pharmaceutical fields. He touted his company's partnership with Nvidia, AWS and AstraZeneca for a research project related to drug development. Looking at molecules through a quantum lens will lead to breakthroughs in drug discovery, he suggested.
IonQ is part of the global race to advance quantum computing, De Masi said. He said his company is a major player in cracking RSA, a widely-used encryption algorithm.
"We are racing China, we believe, almost single handedly, for the Western world, if you will, to be the RSA cracker," De Masi said. "And, of course, when that happens, everybody's going to need our quantum networking equipment to make sure that the world as we know it, and civilization as we know it, goes on."
Click here to download Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest smarter.Disclaimer The CNBC Investing Club Charitable Trust owns shares of Alphabet, Microsoft, Amazon and Nvidia.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Could a Quantum Computing Bubble Be About to Pop? History Offers a Clear Answer
Key Points IonQ, Rigetti Computing, D-Wave Quantum, and Quantum Computing have reached valuation levels well beyond those seen during prior stock market bubbles. Each of these companies has recently raised capital through a series of equity offerings and stock issuances. These moves could suggest that the valuation levels for these businesses are not only abnormally high, but unsustainable. These 10 stocks could mint the next wave of millionaires › Last summer, companies such as IonQ (NYSE: IONQ), Rigetti Computing (NASDAQ: RGTI), D-Wave Quantum (NYSE: QBTS), and Quantum Computing (NASDAQ: QUBT) were unknown penny stocks. However, as quantum computing steadily made its way toward center stage in the artificial intelligence (AI) realm, each of these companies witnessed meteoric rises in their share prices. Over the last 12 months, IonQ stock has blasted higher by 517%, while Rigetti, D-Wave, and Quantum Computing have experienced surges of at least 1,500% as of this writing (July 21). With valuations reaching historically high levels, could investors be on the verge of witnessing a quantum computing bubble bursting? Is quantum computing in a bubble? The chart below illustrates valuation trends among popular quantum computing stocks on a price-to-sales (P/S) basis. As I outlined in a prior article, the quantum computing stocks above are trading at far higher P/S multiples compared to levels seen during the dot-com and COVID-19 stock bubbles. For example, during the internet boom in the late 1990s, stocks such as Amazon, Cisco, and Microsoft experienced peak P/S ratios in the range of 30x and 40x. Taking this a step further, popular COVID stocks such as Zoom Communications and Peloton saw P/S multiples top out at 124x and 20x, respectively. The big theme here is that IonQ, Rigetti, D-Wave, and Quantum Computing are each trading for valuation multiples that could be seen as historically high, even when compared to prior bubble events. With that said, other AI companies that are also exploring quantum computing -- such as Nvidia, Amazon, Alphabet, and Microsoft -- currently trade for much more reasonable valuation multiples when compared to the companies in the chart above. For this reason, I do not think the entire quantum computing landscape is at risk of experiencing a bubble-bursting event. However, IonQ and its peers have been dropping some breadcrumbs in recent months that lead me to think the smaller quantum computing players could be on the verge of a harsh sell-off. What's going on under the hood with quantum computing stocks? After some digging into certain filings with the Securities and Exchange Commission (SEC), I think IonQ, Rigetti, D-Wave, and Quantum Computing may be trying to signal some important things to investors: In February, IonQ announced that it planned to raise up to $500 million through a series of stock issuances. The company doubled down on its capital-raising ambitions more recently, offering 14,165,708 shares at a price of $55.49 -- raising nearly $1 billion in the process. In June, Rigetti raised $350 million in capital after completing an at-the-market (ATM) equity offering. Between June 11 and June 27, D-Wave Quantum raised $400 million through an ATM offering. Of note: This followed a prior raise of $150 million that occurred in January. In late June, Quantum Computing raised $200 million following the issuance of 14 million shares at an average price of $14.25. What's really going on here? With each of these quantum computing stocks trading near all-time highs, it appears to me that management is looking to take advantage of frothy market conditions. Quantum computing is a research-heavy, capital-intensive industry. Management at IonQ and its peers surely understand this, and so I see these capital raises as a calculated move to capitalize on inflated, overstretched valuations. Should you invest in quantum computing stocks? To me, any hint of a bubble surrounding IonQ and its smaller peers may already be in the process of bursting. Under the surface, the various stock issuances and equity offerings annotated above could suggest that management does not believe current price levels are sustainable. By using the dot-com and COVID bubbles as benchmarks, history would suggest that a major correction could be on the horizon for these small quantum computing stocks. Issuing stock to raise funds is not sustainable in the long run. Furthermore, consistently diluting shareholders through these offerings could call into question how these companies are allocating capital. In my eyes, if investors are seeking exposure to the quantum computing industry, they are best off exploring more diversified opportunities in big tech as opposed to the smaller, more speculative players analyzed in this piece. Trump's Tariffs Could Create $1.5 Trillion AI Gold Rush The Motley Fool's analysts are tracking a massive shift in U.S. tech. Over $1.5 trillion is already flowing into infrastructure, AI, and advanced manufacturing… and the number keeps climbing. Following a major tariff policy shift, a new AI Gold Rush is taking shape, and we think . It builds the tech infrastructure that Apple, OpenAI, and others suddenly can't live without. We just released a full write-up on this under-the-radar stock — and why now might be the exact moment to move. Continue » *Stock Advisor returns as of July 21, 2025 Adam Spatacco has positions in Alphabet, Amazon, Microsoft, and Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Cisco Systems, Microsoft, Nvidia, Peloton Interactive, and Zoom Communications. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Could a Quantum Computing Bubble Be About to Pop? History Offers a Clear Answer was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Analysts turn heads with new Alphabet stock price target after earnings
Analysts turn heads with new Alphabet stock price target after earnings originally appeared on TheStreet. Alphabet's solid earnings have investors feeling more confident in Google again. The company posted earnings of $2.31 per share on revenue of $96.43 billion, both ahead of Wall Street analysts' forecast. Search brought in $54.19 billion, while total ad revenue climbed to $71.34 billion, up 10% from last year. YouTube ads came in at $9.8 billion, slightly above expectations. Cloud was a standout, with revenue jumping 32% to $13.62 billion. Alphabet recently struck a deal with OpenAI to power ChatGPT using Google Cloud. Alphabet also raised its 2025 capital spending forecast to $85 billion, up from $75 billion in February, citing 'strong and growing demand for our Cloud products and services.' CFO Anat Ashkenazi said spending will likely increase again in 2026. The upbeat report helped push Alphabet stock () closer to its all-time high. Shares closed at $194.08 on July 25, up more than 13% over the past month. That mirrors a broader bounce in tech stocks as optimism grows around AI and cloud. So far this year, however, Alphabet shares are still trailing the market, up just 1.91% compared to the S&P 500's 8.62% gain. Analysts raise Alphabet's stock price targets Alphabet's latest earnings beat has prompted a wave of price target hikes from Wall Street analysts, though opinions split on how much upside is left. Bank of America analyst Justin Post raised his price target on Alphabet to $217 from $210 while maintaining a buy rating, following the company's better-than-expected second-quarter analyst highlighted that both Cloud and Search outperformed expectations, calling them 'a bright spot' in what he described as 'another strong' quarter that suggests AI use is growing the market. "Another stable qtr for Search results increases our confidence in the AI transition and should ease concerns on a potential revenue reset," the analyst wrote. "We acknowledge growing users of OpenAI but think Street could be underappreciating potential AI driven upside for Search (more use, better ads) and Cloud," he added. JPMorgan raised its price target on Alphabet to $232 from $200 and reiterated an overweight rating, according to The firm believes Alphabet's AI-driven demand and accelerating backlog make Google Cloud a "bigger driver of the bull case going forward." Other firms also lifted their targets following the earnings beat, though with a more cautious tone. Stifel raised its price target on Alphabet to $222 from $218, citing solid performance across Search, YouTube, and Cloud. However, the firm doesn't expect much follow-through in shares due to lingering concerns about Alphabet's long-term AI position and the DOJ overhang. UBS bumped its target to $202 from $192, calling the quarter Alphabet's 'cleanest' in a while, with strong fundamentals supporting earnings growth. Still, the firm kept a neutral rating, pointing to pressure on the stock's valuation from unresolved regulatory risks and rising competition in Search. Google still faces pressure Despite Alphabet's strong earnings, concerns around regulatory and competitive threats still exist. The company is currently facing a major antitrust lawsuit from the U.S. Department of Justice. In early August 2024, Judge Amit Mehta of the U.S. District Court for the District of Columbia accused Google of illegally maintaining a search engine monopoly by using exclusive agreements with device makers like Apple () .The DOJ is now pursuing remedies that include forced divestitures of Chrome and Android. The case is still pending, but could lead to structural changes or costly settlements if the DOJ prevails. Mehta said he aims to rule by August, Reuters reported. Beyond regulatory headwinds, Alphabet is also under mounting pressure from emerging AI competitors. More Wall Street Analysts: Veteran analyst drops surprise call on Tesla ahead of earnings Best Buy analyst, focused on earnings growth, reworks stock price target Microsoft analysts reboot stock price targets ahead of Q4 earnings As generative AI reshapes how users find information, traditional search is being challenged by AI tools like ChatGPT. These platforms offer more conversational responses, potentially reducing the need for users to 'Google.' There's also a risk that trade tensions could curb advertiser spending on Google's platforms, potentially impacting revenue growth. But when asked about the outlook, Alphabet's Chief Business Officer Philipp Schindler said it was too soon to make any calls. 'I think it's really too early to comment on anything happening in the second half of the year,' Schindler turn heads with new Alphabet stock price target after earnings first appeared on TheStreet on Jul 26, 2025 This story was originally reported by TheStreet on Jul 26, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Pharma sector outlook as Trump's drug tariff deadline looms
Pharmaceutical stocks are in focus as President Trump's drug tariff deadline looms. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination with Josh Lipton to discuss the impact that pharmaceutical tariffs could have on the sector, Astrazeneca's (AZN) $50 billion commitment to US investments, and how the industry is navigating pressure from Washington and shifting global demand. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Pharmaceutical stocks in focus as we approach President Trump's looming drug tariff deadline. For more, I want to bring in Yahoo Finance senior health reporter Angelique Chenge. That's right, Josh. With that looming deadline, potentially August 1st, for up to 200% in tariffs, we don't know what that number will actually end up being. We've heard from several companies that have announced manufacturing commitments in hopes to thwart that effort. That includes AstraZeneca. We spoke to CEO Pascal Soriot about that, and he did mention that the announcement for $50 billion, that's in addition to $3.5 billion last year, is in part a response to Trump's tariffs. We know others like Eli Lilly and Johnson & Johnson have also announced similarly big announcements of commitments for manufacturing. And this is in play at a time where the industry is also going through a bit of tumult. We know that there is a lot of investment in one of Trump's least favorite countries, that is China. That is the reason why there has been a lot of tension in the biotech world. We also know that big pharma has been pivoting and investing there as well. Licensing deals and the like are on the rise as they look to sort of respond to all the different countries that are looking for what has now been termed health sovereignty. And this plays into that. So, when I asked Pascal about that, about China and the deal making there, here's what he had to say about it. We believe that it's our ethical responsibility to bring medicines to as many people as possible. Of course, there are limitations to what we can do, but we work very hard to do this. And we are lucky enough or good enough or both, that we are growing. And growth brings opportunities. And because we are growing, we are able to invest in United States for the United States, we're able to invest in China for China, and we're also able to seek innovation where it happens. Because actually, if innovation happens in China or in Europe, we need to take this innovation, develop it, and bring it to patients for instance in the United States, but manufacture the product in the United States. Um, and I think that brings me to an important point that people don't talk enough about is that today innovation in our industry takes place in the U.S. U.S. is the biggest innovator for biopharmaceuticals. And it's really important that everything is done to protect that innovation. It's a fantastic engine to bring new medicines to patients but also create good jobs, well-paid jobs, and economic growth. So, as you can hear, a lot of focus on that, on economic growth being the driver as well and needing to respond to these countries and their efforts. AstraZeneca also talked about how it would help shift revenues for the portfolio with a greater reliance on the U.S. Currently, 42% of revenues comes from the U.S. And with this increase in manufacturing, it would be 50%. And that includes GLP-1s. We know that there's a lot of global demand for that drug and for those types of drugs. AstraZeneca has been pursuing an oral form or pill form, which is largely seen as the next frontier in this space. AstraZeneca looking at being able to then supply the rest of the world from the U.S., making it a larger exporter. So, here's what Pascal said about that. It's also a reason, another reason why we are investing in this very large facility. We have our oral GLP-1. Everybody knows GLP-1 by now. These are agents used to help people manage their weight. We have an oral agent, and we have bet on oral agents because we think they are going to be easier for patients, because they will be cheaper, they'll be more accessible, and we will be able to export them around the world, not only supply America. But we also have other products treating cardiovascular metabolic disease. We have a new agent for hypertension for patients who are not controlled on multi-medicines. We have an oral PCSK9 for the control of cholesterol and many others. Cardiovascular metabolic diseases are the biggest killer in the world today, including in the United States. So, you can see the needs are enormous. This plant will supply products for American patients, so American patients will access products that are American-made. But this plant will also export to the billions of patients around the world who need these medicines. The company really moving that pot of money, you know, globally and looking at where it makes the most sense. Pascal also did tell me that in looking at the different areas of the world where the money can be, you know, invested, China, of course, being one of them. And then if you compare the amount that has been put in there, that is $5.3 billion is one of the latest deals that AstraZeneca has done in China. And if you compare that to the $50 billion, while not on the same level, you can still see it's quite a large number. And that's just one of those deals. So, we're starting to see a little bit of bifurcation in how the global pharmaceutical economy is functioning. Related Videos Uncertainty is 'here to stay': What that means for markets BlackRock's Rick Rieder: I Think Rates Can Come Down Elon Musk's 'master plan': Is Tesla an EV maker or AI play? 'We ask for more data' than FICO: VantageScore CEO Sign in to access your portfolio
